Skip to content
Screener

Baxter International BAX Injectables & Anesthesia — Net Sales

Other product segments

Infusion Therapies & Technologies
$981M-1.3%
Care & Connectivity Solutions
$435M+1.9%
Drug Compounding
$320M+30.1%
Advanced Surgery
$304M+13.4%
Front Line Care
$270M-2.5%

Similar metrics at other companies

General Mills logo
GISPet — Net Sales
$746.6M+5.8%
Wabash National logo
WNCNew trailers — Net Sales
$317.05M+1.6%
Amazon logo
AMZNNet product sales — Net Sales
$71.3B+11.5%
Amazon logo
AMZNNet service sales — Net Sales
$110.22B+20.2%
Lowe's Companies logo
LOWOther Sales — Net Sales
$551M+30.0%
Lowe's Companies logo
LOWPaint Sales — Net Sales
$1.25B+0.4%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$14.13B+22.3%
Enterprise value$12.33B+22.1%
P/S1.3×+0.2×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Baxter International’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:50 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028962
(in millions)Three Months Ended March 31, 2026 / U.S.Three Months Ended March 31, 2026 / InternationalThree Months Ended March 31, 2026 / TotalThree Months Ended March 31, 2025 / U.S.Three Months Ended March 31, 2025 / InternationalThree Months Ended March 31, 2025 / Total
Care & Connectivity Solutions315120435316111427
Front Line Care1987227020275277
Healthcare Systems & Technologies513192705518186704
Injectables & Anesthesia180121301195140335
Drug Compounding320320246246
Pharmaceuticals180441621195386581
Other513990483078
Total Baxter$1,435$1,266$2,701$1,490$1,135$2,625

Item 1. Financial Statements (unaudited)

FAQ

What is Baxter International's injectables & anesthesia — net sales?
Baxter International (BAX) reported injectables & anesthesia — net sales of $301M in Q1 2026.
How has Baxter International's injectables & anesthesia — net sales changed year-over-year?
Baxter International's injectables & anesthesia — net sales decreased by 10.1% year-over-year, from $335M to $301M.
What is the long-term trend for Baxter International's injectables & anesthesia — net sales?
Over 3 years (2021 to 2025), Baxter International's injectables & anesthesia — net sales has grown at a -0.9% compound annual growth rate (CAGR), from $1.39B to $1.35B.
What does injectables & anesthesia — net sales mean?
This metric represents the total revenue generated from the sale of injectable pharmaceutical products and anesthesia-related supplies. It reflects the commercial performance of the company's specialized clinical portfolio used in surgical and critical care settings. Monitoring this segment provides insight into the demand for essential hospital consumables and the company's market penetration in the acute care pharmaceutical space.

Ask your AI about Baxter International's injectables & anesthesia — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude